No association of apolipoprotein E ε4 genotype with faster progression or less recovery of relapses in a Spanish cohort of multiple sclerosis

Multiple Sclerosis

Volumn 12, Issue 1, 2006, Pages 13-18

  Sedano, Ma José ^a   Calmarza, P ^a   Perez, L ^a   Trejo, J M ^a  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

Author keywords

Apolipoprotein E; MS progression; MS relapse recovery; Multiple sclerosis

Indexed keywords

APOLIPOPROTEIN E4;

ADULT; ARTICLE; COHORT ANALYSIS; CONVALESCENCE; DISABILITY; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DNA POLYMORPHISM; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; RELAPSE; REMISSION; SPAIN;

ADULT; AGE OF ONSET; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SPAIN;

EID: 31644431674     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135248506ms1243oa     Document Type: Article

References (33)

1. Weinshenker BG, Kantarci OH. Seeking genes for MS: big risk for big gains. Neurology 2000; 54: 542-44.
2. Mahley R. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1998; 240:622-30.
3. Beffert U, Danik M, Kryzwkowski P, Ramassamy C, Berrada F, Poirier J et al. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. Brain Res Rev 1998; 27: 119-42.
4. Poirier J. Apolipoprotein E in the brain and its role in Alzheimer's disease. J Psychiatr Neurosci 1996; 21: 128-34.
5. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH et al. Association of apolipoprotein E allele E4 with late onset familial and sporadic Alzheimer disease. Neurology 1993; 43: 1467-72.
6. Weatherby SJ, Mann CL, Davies MB, Carthy D, Fryer A, Boggild MD et al. Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis. Mult Scler 2000; 6: 32-36.
7. Masterman T, Zhang Z, Hellgren D, Salter H, Anvret M, Lilius L et al. APOE Genotypes and disease severity in multiple sclerosis. Mult Scler 2002; 8: 98-103.
8. Ferri C, Sciacca FL, Veglia F, Martinelli F, Comi G, Canal N et al. APOE ε2-4 and -491 polymorphisms are not associated with MS. Neurology 1999; 53: 888-89.
9. Savettieri G, Andreoli U, Bonavita S, Citadella R, Caltagirone C, Fazio MC et al. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. J Neurol 2003; 250: 1094-98.
10. Guerrero AL, Bueno V, Hernandez MT, Martín-Serradilla JI, Carrasco E, Cuadrado I. Apolipoprotein E polymorphism, as predictor of progression of multiple sclerosis. Neurologia 2003; 18: 146-48.
11. Santos M, do Carmo Costa M, Edite Rio M, Jose Sa M, Monteiro M, Valenca A et al. Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin. Mult Scler 2004; 10:153-57.
12. Zwemmer JN, van Veen T, van Winsen L, van Kamp GJ, Barkhof F, Polman CH et al. No major association of Apo E genotype with disease characteristics and MRI findings in multiple sclerosis. Mult Scler 2004; 10: 272-77.
13. 4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 67: 203-205.
14. Hogh P, Oturai A, Schreiber K, Blinkenberg M, Jorgensen O, Ryder L et al. Apolipoprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Mult Scler 2000; 6: 226-30.
15. Chapman J, Vinokurov S, Achiron A, Karussis DM, Mitosek-Szewczyk K, Birnbaum M et al. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 2001; 56: 312-16.
16. Fazekas F, Strasser-Fuchs S, Kolleger H, Berger T, Kristoferictsch W, Schmidt H et al. Apolipoprotein E ε4 is associated with rapid progression of multiple sclerosis. Neurology 2001; 57: 853-57.
17. Frederiksen JL, Pinholt M, Christiansen M, Andersen P, Glostrup KAS. Association between apolipoprotein E, multiple sclerosis and acute monosymptomatic opticus neuritis. Mult Scler 2004; 11: P443 (Abstract).
18. Poser CM, Paty DW, Scheinberg L, McDonald WI. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
19. Sipe JC, Knobler RL, Braheny SL, Rice GP, Panitch HS, Oldstone MB. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984; 34: 1368-72.
20. Runmarker B, Anderson C, Oden A, Andersen O. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol 1994; 241: 597-604.
21. Muros M, Rodríguez-Ferrer C. Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp(a) in a Spanish population underexpressing apoE4. Atherosclerosis 1996; 121: 13-21.
22. Gomez-Coronado D, Alvarez JJ, Entrala A, Olmos JM, Herrera E, Lasuncion MA et al. Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins. Atherosclerosis 1999; 147: 167-76.
23. Lucotte G, Loirat F, Hazout S. Pattern of gradient of apolipoprotein E allele ε4 frequencies in western Europe. Hum Biol 1997; 69: 253-62.
24. Vincent S, Planells R, Defoort C, Bernard MC, Gerber M, Prudhomme J et al. Genetic polymorphism and lipoprotein responses to diets. Proc Nutr Soc 2002; 61: 427-34.
25. Ribalta J, Vallve JC, Girona J, Masana L. Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. Curr Opin Clin Nutr Metab Care 2003; 6: 177-87.
26. Weggemans RM, Zock PL, Ordovas JM, Pedro-Botet J, Katan MB. Apoprotein E genotype and the response of serum cholesterol to dietary fat, cholesterol and cafestol. Atherosclerosis 2001; 154: 547-55.
27. Couture P, Archer WR, Lamarche B, Landry N, Deriaz O, Corneau L et al. Influences of apolipoprotein E polymorphism on the response plasma lipids to the ad libitum consumption of a high-carbohydrate diet compared with a high-monounsaturate fatty acid diet. Metabolism 2003; 52: 1454-59.
28. Burgos JS, Ramirez C, Sastre I, Bullido MJ, Valdivielso F. ApoE4 is more efficient than E3 in brain access by herpes simples virus type I. Neuroreport 2003; 14: 1825-27.
29. Becker KG. APOE genotype is a major predictor of longterm progression of disability in MS. Neurology 2001; 57: 2148-49.
30. Sadovnick AD, Dyment D, Ebers C. Genetic epidemiology of multiple sclerosis. Epidemiol Rev 1997; 19: 99-106.
31. Kantarci OH, Hebrink DD, Achenbach SJ, Pittock SJ, Altintas A, Schaefer-Klein JL et al. Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology 2004; 62: 811-14.
32. De Stefano N, Bartolozzi ML, Nacmias B, Zipoli V, Mortilla M, Guidi L et al. Influence of apolipoprotein E ε4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. Arch Neurol 2004; 61: 536-40.
33. Enzinger C, Ropele S, Smith S, Strasser-Fuchs S, Poltrum B, Schmidt H et al. Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-ε4. Ann Neurol 2004; 55: 563-69.